Efficacy of peritoneal dialysis of tolbutamide in rats under conditions of the plasma unbound fraction being increased

Biopharmaceutics and Drug Disposition

Volumn 30, Issue 1, 2009, Pages 1-8

  Makita, Takashi ^a   Aiba, Tetsuya ^a   Izuwa, Yuki ^a   Komori, Yukiko ^a   Kawasaki, Hiromu ^a   Kurosaki, Yuji ^a  

^a OKAYAMA UNIVERSITY   (Japan)

Author keywords

Acute renal failure; Peritoneal dialysis; Protein binding; Sulfonamides; Tolbutamide

Indexed keywords

PLASMA PROTEIN; SULFADIMETHOXINE; SULFAMETHOXAZOLE; SULFONAMIDE; TOLBUTAMIDE;

ACUTE KIDNEY FAILURE; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BLOOD LEVEL; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DIALYSATE; DIFFUSION; DRUG CLEARANCE; MALE; MEMBRANE TRANSPORT; NONHUMAN; PERITONEAL DIALYSIS; RAT;

ALGORITHMS; ANIMALS; ANTI-INFECTIVE AGENTS; AREA UNDER CURVE; BLOOD PROTEINS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG INTERACTIONS; HYPOGLYCEMIC AGENTS; MALE; MODELS, STATISTICAL; PERITONEAL DIALYSIS; PLASMA; PROTEIN BINDING; RATS; RATS, WISTAR; SULFADIMETHOXINE; TOLBUTAMIDE;

EID: 59949090876     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.640     Document Type: Article

References (15)

1. Rowland M, Tozer TN. Clinical Pharmacokinetics, 3rd edn. Baltimore: Williams and Wilkins, 1995; p. 443-462.
2. Kishino S, Takekuma Y, Sugawara M et al. Influence of continuous venovenous haemodiafiltration on the pharmacokinetics of tacrolimus in liver transplant recipients with small-for-size grafts. Clin Transplant 2003; 17: 412-416.
3. Flessner MF. Peritoneal transport physiology: insights from basic research. J Am Soc Nephrol 1991; 2: 122-135.
4. Thiessen JJ, Sellers EM, Denbeigh P, Dolman L. Plasma protein binding of diazepam and tolbutamide in chronic alcoholics. J Clin Pharmacol 1976; 16: 345-351.
5. Sugita O, Sawada Y, Sugiyama Y, Iga T, Hanano M. Prediction of drug-drug interaction from in vitro plasma protein binding and metabolism. A study of tolbutamide-sulfonamide interaction in rats. Biochem Pharmacol 1981; 30: 3347-3354.
6. Otagiri M, Nakamura H, Maruyama T, Imamura Y, Takadate A. Characterization of binding sites for sulfadimethoxine and its major metabolite, N4-acetylsulfadimethoxine, on human and rabbit serum albumin. Chem Pharm Bull 1989; 37: 498-501.
7. Tanaka M, Asahi Y, Masuda S, Minagawa K. Binding position of tolbutamide to human serum albumin. Chem Pharm Bull 1998; 46: 817-821.
8. Aiba T, Horiuchi M, Makita T, Komori Y, Kawasaki H, Kurosaki Y. Peritoneal dialysis alters tolbutamide pharmacokinetics in rats with experimental acute renal failure. Drug Metab Pharmacokinet 2006; 21: 291-296.
9. Kaplan B, Meier-Kriesche HU, Friedman G et al. The effect of renal insufficiency on mycophenolic acid protein binding. J Clin Pharmacol 1999; 39: 715-720.
10. Mabuchi H, Nakahashi H. A major inhibitor of phenytoin binding to serum protein in uremia. Nephron 1988; 48: 310-314.
11. Tsutsumi Y, Maruyama T, Takadate A, Shimada H, Otagiri M. Decreased bilirubin-binding capacity in uremic serum caused by an accumulation of furan dicarboxylic acid. Nephron 2000; 85: 60-64.
12. Rippe B, Stelin G, Haraldsson B. Computer simulations of peritoneal fluid transport in CAPD. Kidney Int 1991; 40: 315-325.
13. Takanaga H, Murakami H, Koyabu N et al. Efflux transport of tolbutamide across the blood-brain barrier. J Pharm Pharmacol 1998; 50: 1027-1033.
14. Brown NM, Reeves DS, McMullin CM. The pharmacokinetics and protein-binding of fusidic acid in patients with severe renal failure requiring either haemodialysis or continuous ambulatory peritoneal dialysis. J Antimicrob Chemother 1997; 39: 803-809.
15. Puttonen J, Kantele S, Kivikko M et al. Effect of severe renal failure and haemodialysis on the pharmacokinetics of levosimendan and its metabolites. Clin Pharmacokinet 2007; 46: 235-246.